Danielle Ternyila

In an interview with Targeted Oncology, Ghassan K. Abou-Alfa, MD, discussed the evolution of the liver cancer treatment landscape and recognizes some of most important advances in the field during Liver Cancer Awareness Month.

In an interview with Targeted Oncology, Daniel A. Vorobiof, MD, discussed the evolution of the breast cancer treatment landscape and the emerging role of genomic testing in this space during Breast Cancer Awareness Month.

A New Drug Application for pacritinib is planned to be submitted for potential accelerated approval from the FDA for the treatment of patients with myelofibrosis and severe thrombocytopenia.

A review was conducted to understand how precision medicine strategies can be successfully implemented in diffuse large B-cell lymphoma

Relugolix demonstrated a similar rate of castration resistance-free survival compared with the current standard of care leuprolide acetate as treatment of patients with metastatic prostate cancer.

Camrelizumab plus apatinib demonstrated a high objective response rate and disease-control rate, as well as durable responses and long survival as treatment of patients with advanced hepatocellular carcinoma, according to the results from the phase 2 RESCUE clinical trial.

In an interview with Targeted Oncology, Tanja Gruber, MD, PhD, discussed the advances she has observed in recent years for the treatment of pediatric patients, including the evolving role of CAR T-cell therapy.

In an interview with Targeted Oncology, David Roberge, MD, discussed the role of radiation treatment in patients with brain metastases and the clinical trial evaluating treatment approaches for patients with more than 5 brain metastases.

Some of the most exciting new data at this year’s congress included advancements in lung cancer, breast cancer, genitourinary cancers, and gastrointestinal cancers. Several experts spoke with Targeted Oncology to share their thoughts on some of the most impactful abstracts from the 2020 ESMO Congress.

Targeted Oncology reviews trending news online for the week of September 25, 2020, including updates in oncology and new information regarding COVID-19.

Raajit K. Rampal, MD, PhD, discussed the role of genomics in the treatment landscape of myelofibrosis and the remaining challenges that need to be addressed in order to use this information more effectively to treat patients and improve outcomes.

The FDA granted a Priority Review designation to idecabtagene vicleucel as treatment of adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

Larotrectinib as treatment of patients with TRK fusion-positive thyroid cancer had rapid and durable disease control, with the highest response rates observed in the differentiated thyroid cancer population.

Larotrectinib demonstrated rapid and durable as treatment of patients with TRK fusion-positive solid tumors, as well as a favorable long-term toxicity profile, according to an expanded pooled analysis from 3 clinical trials.

A significant improvement in overall survival was observed with the addition of hepatic arterial infusion chemotherapy to oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.

In an interview with Targeted Oncology, Naveen Pemmaraju, MD, discussed recent advances for the treatment of patients with MPNs and shared his thoughts on recent hematologic meetings and the growing role of social media during the COVID-19 pandemic.

The global phase 3 EV-301 study of enfortumab vedotin-ejfv in adult patients with locally advanced or metastatic urothelial carcinoma who received prior platinum-based chemotherapy and a PD-1/PD-L1 inhibitor met its primary end point of overall survival compared with chemotherapy.

Targeted Oncology reviews trending news online for the week of September 18, 2020, including updates in oncology, and new information regarding COVID-19.

The incidence of disease progression in patients with familial adenomatous polyposis was not significantly lower when patients were treated with eflornithine plus sulindac compared with either drug alone.

The 2020 SOHO Annual Meeting held true to the theme of “Molecular Classification and Precision Therapy” with emphasis on novel therapeutic approaches in hematologic malignancies.

In an interview with Targeted Oncology, Sara A. Hurvitz, MD, reviewed the 4 currently approved treatment options for patients with HER2-positive breast cancer and discussed how physicians could use the data to make treatment decisions in the adjuvant and neoadjuvant setting.

“In sum, these data show that T300+D regimen provides the best benefit-to-risk profile across arms,” Robin Kate Kelley, MD, said of Study 22 in hepatocellular carcinoma.

In an interview with Targeted Oncology, Thomas M. Habermann, MD, reflects on the advancements he has observed in the treatment paradigm for lymphomas.

The FDA has granted a Breakthrough Therapy designation to magrolimab as treatment of patients with newly diagnosed myelodysplastic syndrome.

In an interview with Targeted Oncology, Prithviraj Bose, MD, discussed the disease outcomes for patients with essential thrombocythemia, as well as the unmet needs and therapeutic strategies available in this space.

Regorafenib demonstrated a tolerable safety profile as treatment of patients with unresectable hepatocellular carcinoma in the real world, according to results from the ongoing prospective observational REFINE study.

Binimetinib demonstrated activity as treatment of patients with low-grade serous ovarian carcinomas in the randomized phase 3 MILO/ENGOT-ov11 study.

The FDA has granted a Breakthrough Therapy designation to toripalimab for the treatment of patients with nasopharyngeal carcinoma, marking the first anti-PD-1 antibody from China to receive this designation.

Targeted Oncology reviews trending news online for the week of September 11, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

A supplemental Biologics License Application has been submitted to the FDA seeking approval of a subcutaneous formulation of daratumumab with hyaluronidase-fihj as treatment of patients with light chain amyloidosis.